Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy Extension Study of rIX-FP in Hemophilia B
NCT02053792Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Feb 2014
- Primary completion
- Jun 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 15
01
Overview
A Phase 3 trial of albutrepenonacog alfa in hemophilia B (HB), sponsored by CSL Limited. Started Feb 2014; status: completed.
02
Drugs
albutrepenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT02053792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053792.